Mitochondrial diseases are primarily genetic disorders that are essential for encoding proteins involved in mitochondrial function and generating energy as ATP through oxidative phosphorylation (OXPHOS). This causes mitochondrial dysfunction and energy deficits in the cell, affecting organs and tissues with high energy demands\u00a0(e.g., the heart, kidneys, brain, eyes, and skeletal muscle). Passed from mother to child, mitochondrial diseases affect 1 in 5,000-10,000 children. On the rise, however, there are reproductive technologies that allow the replacement of defective mitochondrial DNA with healthy donor mitochondria. While there are concerns about safety and efficacy, and questions about legality, regulations, and ethics, I am for the use of mitochondrial DNA replacement therapy under proper circumstances.\u00a0\u00a0\u00a0<\/p>\n\n\n\n
Mitochondrial DNA replacement therapy, as described above, substitutes mutated mitochondrial DNA with a new, functional copy. This replacement occurs in unfertilized oocytes and zygotes,\u00a0essentially correcting\u00a0the defect before engineering the child\u2019s entire genome during pregnancy. One technique used in mitochondrial replacement therapy is spindle transfer (ST), which involves removing the spindle from a mature oocyte and inserting it into an enucleated donor egg. A new, healthy egg free of mutated mitochondrial DNA is constructed and is ready to be fertilized and transferred back to the patient.\u00a0\u00a0<\/p>\n\n\n\n
While there is promise for treating inherited diseases, there are also valid questions and concerns. Some current issues\u00a0cite\u00a0the possibility of procedural failure and of abnormalities arising from mismatches between nuclear and mitochondrial genomes. Another is the lack of proper global guidelines that ensure the safety and effectiveness of these procedures. Also, there is a genetic connection to three parents: mother, father, and mitochondrial donor, which might make it misleading for the child. Qualified as germ-line therapy, this is still new and experimental. This means trials are ongoing, and there is limited data on the long-term effects. It is a highly controversial topic that needs to be discussed; however, if done right, it can cure otherwise untreatable diseases.\u00a0\u00a0\u00a0<\/p>\n\n\n\n
Despite unease, addressing these questions ensures safe and\u00a0responsible\u00a0technology use. Research suggests that failures, such as carryover of mutated mitochondrial DNA, are minimal, and primate studies show long-term compatibility with no abnormalities. Ongoing efforts in countries like England, the US, and Japan are assessing safety and effectiveness. I believe that\u2014with the right research, regulations, and guidelines\u2014mitochondrial DNA replacement therapy gives families a crucial\u00a0option\u00a0to break the cycle of inherited disease. Its promise outweighs uncertainties when it can prevent serious health problems in children.\u00a0<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
References<\/p>\n\n\n\n
Di Donfrancesco, Alessia, et al. \u201cGene Therapy for Mitochondrial Diseases: Current Status and Future Perspective.\u201d Pharmaceutics, vol. 14, no. 6, June 2022, p. 1287. https:\/\/doi.org\/10.3390\/pharmaceutics14061287.<\/p>\n\n\n\n
Mitalipov, Shoukhrat, and Don P. Wolf. \u201cClinical and Ethical Implications of Mitochondrial Gene Transfer.\u201d Trends in Endocrinology and Metabolism, vol. 25, no. 1, Dec. 2013, pp. 5\u20137. https:\/\/doi.org\/10.1016\/j.tem.2013.09.001.<\/p>\n\n\n\n
Sendra, Luis, et al. \u201cMitochondrial DNA Replacement Techniques to Prevent Human Mitochondrial Diseases.\u201d International Journal of Molecular Sciences, vol. 22, no. 2, Jan. 2021, p. 551. https:\/\/doi.org\/10.3390\/ijms22020551.<\/p>\n\n\n\n
Sharma, Hitika, et al. \u201cDevelopment of Mitochondrial Replacement Therapy: A Review.\u201d Heliyon, vol. 6, no. 9, Sept. 2020, p. e04643. https:\/\/doi.org\/10.1016\/j.heliyon.2020.e04643.<\/p>\n\n\n\n
Yamada, Mitsutoshi, et al. \u201cMitochondrial Replacement by Genome Transfer in Human Oocytes: Efficacy, Concerns, and Legality.\u201d Reproductive Medicine and Biology, vol. 20, no. 1, Nov. 2020, pp. 53\u201361. https:\/\/doi.org\/10.1002\/rmb2.12356.<\/p>\n\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Mitochondrial diseases are primarily genetic disorders that are essential for encoding proteins involved in mitochondrial function and generating energy as ATP through oxidative phosphorylation (OXPHOS). This causes mitochondrial dysfunction and energy deficits in the cell, affecting organs and tissues with… Continue Reading →<\/a><\/p>\n","protected":false},"author":31223,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","wds_primary_category":0},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/posts\/233"}],"collection":[{"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/users\/31223"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/comments?post=233"}],"version-history":[{"count":1,"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/posts\/233\/revisions"}],"predecessor-version":[{"id":235,"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/posts\/233\/revisions\/235"}],"wp:attachment":[{"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/media?parent=233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/categories?post=233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/tags?post=233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}